Feed Top Reports Pricing

⌘K

00:15:02·324d

SECFiling

SEC Form EFFECT filed by bluebird bio Inc.

BLUE· bluebird bio Inc.

Health Care

Original source

Companies

BLUE
bluebird bio Inc.
Health Care

Recent analyst ratings

Feb 24UpdateAnalyst-
Feb 24UpdateAnalyst$29.00
Nov 15UpdateAnalyst-
Nov 15UpdateJP Morgan-
Nov 15UpdateBofA Securities$0.50
Aug 15UpdateJP Morgan-

Related

SEC316d
SEC Form 15-12G filed by bluebird bio Inc.
INSIDER324d
Chief Business & Legal Officer Vittiglio Joseph returned 5,625 shares to the company and was granted 2,500 shares, closing all direct ownership in the company (SEC Form 4)
INSIDER324d
Director Agwunobi John O returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)
INSIDER324d
Director Vachon Mark returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)
INSIDER324d
Chief Medical Officer Colvin Richard A returned 6,666 shares to the company and was granted 2,500 shares, closing all direct ownership in the company (SEC Form 4)
INSIDER324d
Director Tita-Reid Najoh returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)
INSIDER324d
President and CEO Obenshain Andrew returned 24,120 shares to the company and was granted 14,820 shares, closing all direct ownership in the company (SEC Form 4)
INSIDER324d
Director Leiderman Elisabeth returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022